Loading clinical trials...

Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE3

Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy

NCT07467083•West China Hospital

View on ClinicalTrials.gov

Summary

Detailed Description

The aim of this study is to investigate whether a nurse-led preemptive symptom management protocol can reduce the radiation therapy interruption rate in patients with head and neck cancer compared to conventional care models. The secondary objective is to evaluate whether the nurse-led preemptive symptom management protocol improves symptoms, quality of life, and psychological well-being in head and neck cancer patients undergoing radiation therapy compared to conventional care models.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients had pathologically confirmed malignant head and neck tumors without distant metastasis.
•2. Patient age ≥18 years; Patients were scheduled to undergo either postoperative adjuvant radiotherapy or radical radiotherapy, with or without concurrent chemotherapy.
•3. Baseline ECOG (Eastern Cooperative Oncology Group) score 0-2;
•4. Good cognitive and reading skills, able to complete the questionnaire survey.

Exclusion Criteria

•1. Presence of other malignant tumors aside from head and neck malignancies;
•2. A history of prior head and neck radiotherapy;
•3. Mental illness or cognitive impairments;
•4. Uncontrolled systemic diseases that could significantly affect their QoL.

Key Dates

Start Date

March 1, 2026

Primary Completion Date

March 1, 2027

Completion Date

March 1, 2027

Last Updated

March 12, 2026

Enrollment

170

ESTIMATED participants

Conditions

Head and Neck Cancer

Interventions

Nurse-led preemptive symptom management

BEHAVIORAL

Concentional care

BEHAVIORAL

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750

Advanced Solid TumorAdvanced Malignant Neoplasm+28 more

View study

RECRUITINGNA

An Oncology Nurse AI Agent to Reduce Cancer Distress During Radiotherapy

NCT06636188

Head and Neck Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 12, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy

Inclusion Criteria

Exclusion Criteria

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

An Oncology Nurse AI Agent to Reduce Cancer Distress During Radiotherapy

A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial